RCMI Coordinating Center (RCMI CC) Header Logo

Connection

David Calhoun to Treatment Failure

This is a "connection" page, showing publications David Calhoun has written about Treatment Failure.
Connection Strength

2.431
  1. Acelajado MC, Calhoun DA. Resistant hypertension: who and how to evaluate. Curr Opin Cardiol. 2009 Jul; 24(4):340-4.
    View in: PubMed
    Score: 0.351
  2. Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich). 2007 Jan; 9(1 Suppl 1):19-24.
    View in: PubMed
    Score: 0.296
  3. Calhoun DA. Resistant or difficult-to-treat hypertension. J Clin Hypertens (Greenwich). 2006 Mar; 8(3):181-6.
    View in: PubMed
    Score: 0.279
  4. Siddiqui M, Bhatt H, Judd EK, Oparil S, Calhoun DA. Reserpine Substantially Lowers Blood Pressure in Patients With Refractory Hypertension: A Proof-of-Concept Study. Am J Hypertens. 2020 08 04; 33(8):741-747.
    View in: PubMed
    Score: 0.190
  5. Siddiqui M, Judd EK, Dudenbostel T, Zhang B, Gupta P, Tomaszewski M, Patel P, Oparil S, Calhoun DA. Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence. Hypertension. 2019 09; 74(3):652-659.
    View in: PubMed
    Score: 0.176
  6. Calhoun DA, Schiffrin EL, Flack JM. Resistant Hypertension: An Update. Am J Hypertens. 2019 01 01; 32(1):1-3.
    View in: PubMed
    Score: 0.170
  7. Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure. Can J Cardiol. 2016 05; 32(5):603-6.
    View in: PubMed
    Score: 0.133
  8. Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure. Hypertension. 2015 Jul; 66(1):126-33.
    View in: PubMed
    Score: 0.132
  9. Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014 Mar; 63(3):451-8.
    View in: PubMed
    Score: 0.120
  10. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013 Oct; 62(4):691-7.
    View in: PubMed
    Score: 0.117
  11. Calhoun DA. Obstructive sleep apnea and hypertension. Curr Hypertens Rep. 2010 Jun; 12(3):189-95.
    View in: PubMed
    Score: 0.094
  12. Pisoni R, Ahmed MI, Calhoun DA. Characterization and treatment of resistant hypertension. Curr Cardiol Rep. 2009 Nov; 11(6):407-13.
    View in: PubMed
    Score: 0.090
  13. Ahmed MI, Pisoni R, Calhoun DA. Current options for the treatment of resistant hypertension. Expert Rev Cardiovasc Ther. 2009 Nov; 7(11):1385-93.
    View in: PubMed
    Score: 0.090
  14. Ghazi L, Oparil S, Calhoun DA, Lin CP, Dudenbostel T. Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant. Hypertension. 2017 05; 69(5):827-835.
    View in: PubMed
    Score: 0.038
  15. Vemulapalli S, Deng L, Patel MR, Kilgore ML, Jones WS, Curtis LH, Irvin MR, Svetkey LP, Shimbo D, Calhoun DA, Muntner P. National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension. Am Heart J. 2017 Apr; 186:29-39.
    View in: PubMed
    Score: 0.037
  16. Bangalore S, Davis BR, Cushman WC, Pressel SL, Muntner PM, Calhoun DA, Kostis JB, Whelton PK, Probstfield JL, Rahman M, Black HR. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. Am J Med. 2017 Apr; 130(4):439-448.e9.
    View in: PubMed
    Score: 0.036
  17. Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014 Nov; 64(5):1012-21.
    View in: PubMed
    Score: 0.031
  18. Irvin MR, Shimbo D, Mann DM, Reynolds K, Krousel-Wood M, Limdi NA, Lackland DT, Calhoun DA, Oparil S, Muntner P. Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich). 2012 Oct; 14(10):694-700.
    View in: PubMed
    Score: 0.027
  19. Quinaglia T, Martins LC, Figueiredo VN, Santos RC, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H. Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. J Hum Hypertens. 2011 Nov; 25(11):656-64.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support